Medicines New Zealand Guidelines for Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals
The Medicines New Zealand and New Zealand Medical Association (NZMA) Joint Transparency Initiative becomes effective on 1 January 2021. This initiative aims to promote public confidence in the biopharmaceutical industry through increasing transparency around the interactions between Healthcare Professionals and companies from the innovative medicines sector.
The cornerstone of the Transparency Initiative are the voluntary Guidelines For Disclosure Of Transfers Of Value From Pharmaceutical Companies To Healthcare Professionals which were developed by a joint Working Group composed of representatives from Medicines New Zealand’s Member Companies and the NZMA.
Click on the links below to review the Guidelines and also the accompanying Frequently Asked Questions resource.
Transfer of Value Reports 2022
The following companies did not have any transfers of value for 2022
Transfer of Value Reports 2021
The following companies did not have any transfers of value for 2021
